^
20h
Immunogenetic Background of Chronic Lymphoproliferative Disorders in Romanian Patients-Case Control Study. (PubMed, Med Sci (Basel))
Our study indicates that HLA-C*02:02 and HLA-C*12:02 are positively associated with chronic lymphoproliferative disorders for our Romanian patients while HLA-DRB1*11:01, HLA-DRB1*13:02, and HLA-B*35:02 alleles have a protective role against these diseases.
Journal
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B) • HLA-DPB1 (Major Histocompatibility Complex, Class II, DP Beta 1) • HLA-C (Major Histocompatibility Complex, Class I, C)
|
HLA-A*11
3d
The aryl hydrocarbon receptor differentially modulates the expression profile of antibody isotypes in a human B-cell line. (PubMed, Toxicol Sci)
These results suggest that modulation of AhR activity differentially alters the IgH isotypic expression profile and antibody secretion that may be partly dependent on cellular stimulation. Since a variety of chemicals from anthropogenic, industrial, pharmaceutical, dietary, and bacterial sources bind the AhR, the ability of environmental exposures to alter AhR activity (ie activate or inhibit) may have a direct influence on immune function and antibody-relevant disease conditions.
Preclinical • Journal
|
CD40LG (CD40 ligand) • IL4 (Interleukin 4)
5d
Assessment for 11q and other chromosomal aberrations in large B-cell/high-grade B cell lymphomas of germinal center phenotype lacking BCL2 expression. (PubMed, Cancer Genet)
The findings suggest more frequent alterations of 11q in diffuse large B cell lymphoma (DLBCL)/HGBCL-GC BCL2-, in comparison to cases of Burkitt lymphoma (BL) or DLBCL-GC BCL2+, and confirm a low genomic complexity score of BL. Variability identified in patterns of 11q alterations suggests genomic array studies may afford value over FISH testing as we continue to understand HGBCL-11q as a distinct entity, and interrogate cases of DLBCL/HGBCL-GC BCL2-.
Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
16d
Childhood and Adolescent Relapsed/Refractory Aggressive B-Cell Lymphomas With t(8;14) and BCL2 Expression, Burkitt Lymphoma Versus Diffuse Large B-Cell Lymphoma: A Diagnostic Challenge. (PubMed, Pediatr Dev Pathol)
We concluded that both could be diagnosed as "DLBCL-NOS with MYC rearrangement" using the current pathologic classifications, 2022 International Consensus Classification (ICC) and World Health Organization Classifications of Haematolymphoid Tumors (WHO-HAEM5). This report illustrates diagnostic challenges and treatment dilemmas that may be encountered, particularly for adolescent and young adults (AYA).
Journal • IO biomarker
|
TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2)
|
TP53 mutation • BCL2 expression • MYC rearrangement • MYC mutation
19d
SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. (PubMed, Cancer Cell)
Loss of activity for these factors phenocopied aberrant BCL6 activity within murine centrocytes and human Burkitt lymphoma cells. SMARCA4 therefore facilitates chromatin accessibility for TFs that shape centrocyte trajectories, and loss of fine-control of these programs biases toward centroblast cell-fate, GC hyperplasia and lymphoma.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL6 (B-cell CLL/lymphoma 6) • SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SPI1 (Spi-1 Proto-Oncogene)
|
MYC expression • SMARCA4 deletion
1m
Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma (clinicaltrials.gov)
P2, N=348, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Jun 2024
Trial completion date • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
BCL2 expression
|
Rituxan (rituximab)
1m
Williams-Beuren syndrome in pediatric T-cell acute lymphoblastic leukemia: A rare case report and review of literature. (PubMed, Medicine (Baltimore))
To the best of our knowledge, this is the first reported case of WBS in T-cell acute lymphoblastic leukemia. We want to emphasize that the occurrence of leukemia in this patient might be related to the loss of 7q11.23 and microdeletion of 9p21.3 (including 3 TSGs), but the relationship between WBS and malignancy remains unclear. Further studies are required to clarify the relationship between WBS and malignancy.
Review • Journal
|
NOTCH1 (Notch 1) • BCL11B (BAF Chromatin Remodeling Complex Subunit BCL11B) • USP7 (Ubiquitin Specific Peptidase 7)
|
BCL11B mutation
1m
Trial completion
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
Promune (agatolimod)
1m
The Incidence of FISH Abnormalities in Patients with Post-Transplant Lymphomas (PT-NHLs) (USCAP 2024)
FISH analysis of FFPE PT-NHLs detects genetic abnormalities, even in small specimens, in approximately 60% of cases. While BCL2 and BCL6 abnormalities are infrequent, MYC and 11q abnormalities were seen in 1/3 of tested cases. Interestingly, the classic 11q aberration was seen only in GC-DLBCLs (all patients alive), while extra copies were seen in non-GC cases (all patients with follow-up have died), including 2 EBV positive, suggesting different pathogenetic pathways with unique biologic behavior.
Clinical • IO biomarker • Post-transplantation
|
TP53 (Tumor protein P53) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6) • IRF4 (Interferon regulatory factor 4) • MME (Membrane Metalloendopeptidase)
|
TP53 deletion • MYC rearrangement
|
ZytoLight® SPEC 11q gain/loss Triple Color Probe
1m
LMO2 RNA ISH Expression Correlates with LMO2 Protein and Gene Expression and Captures their Survival Impact in Diffuse Large B-Cell Lymphoma, NOS (USCAP 2024)
LMO2 ISH by RNAscope method is reliable and can be applied in routine FFPE samples. Our series had good correlation with LMO2 gene expression and LMO2 IHC. Moreover, the prognostic impact on survival captured by LMO2 RNA ISH was similar to published for gene expression and IHC methods.
LMO2 (LIM Domain Only 2)
|
LMO2 overexpression
|
HTG Transcriptome Panel
1m
KEYNOTE145: ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (clinicaltrials.gov)
P1/2, N=161, Active, not recruiting, Acerta Pharma BV | Phase classification: P1b/2 --> P1/2 | Trial completion date: Dec 2025 --> Apr 2026
Phase classification • Trial completion date • Combination therapy
|
Keytruda (pembrolizumab) • Calquence (acalabrutinib)
1m
Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies (clinicaltrials.gov)
P1, N=33, Recruiting, Medical College of Wisconsin | Trial completion date: May 2028 --> May 2026 | Trial primary completion date: May 2027 --> May 2026
Trial completion date • Trial primary completion date • Combination therapy
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
MYC rearrangement • BCL6 rearrangement
|
Rituxan (rituximab) • cyclophosphamide • etoposide IV • pegylated liposomal doxorubicin • vincristine • prednisone • Zynlonta (loncastuximab tesirine-lpyl) • Marqibo (vincristine liposomal)
1m
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=44, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2023 --> Mar 2025 | Trial primary completion date: Dec 2023 --> Mar 2025
Trial completion date • Trial primary completion date
|
CD19 positive
|
lenalidomide • Blincyto (blinatumomab)
1m
Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma (clinicaltrials.gov)
P1, N=10, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Gene therapy
|
CD34 (CD34 molecule)
|
Rituxan (rituximab) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • etoposide oral • vincristine • prednisone • Neupogen (filgrastim)
1m
Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia (clinicaltrials.gov)
P1, N=37, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date
|
CD19 positive
|
cyclophosphamide • etoposide IV • fludarabine IV • Belrapzo (bendamustine RTD) • CD19 CAR T cells
1m
CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT (clinicaltrials.gov)
P=N/A, N=50, Recruiting, Children's Hospital of Philadelphia | N=30 --> 50 | Trial completion date: Jan 2024 --> Jan 2026 | Trial primary completion date: Jan 2024 --> Feb 2025
Enrollment change • Trial completion date • Trial primary completion date
|
cyclophosphamide
2ms
PROSECO: Immune Responses to COVID-19 Vaccination in Lymphoma Patients (clinicaltrials.gov)
P=N/A, N=592, Completed, University Hospital Southampton NHS Foundation Trust | Active, not recruiting --> Completed
Trial completion
2ms
A Retrospective Cohort Study to Evaluate the Outcomes of HIV-Associated High-Grade B-Cell Non-Hodgkin Lymphoma (NHL) Treated with Dose Adjusted EPOCH (+/-R) Regimen. (PubMed, Indian J Hematol Blood Transfus)
DA-EPOCH(+/-R) is a highly effective regimen in seropositive high-grade B-cell lymphoma, even in the presence of adverse features. The online version contains supplementary material available at 10.1007/s12288-023-01652-3.
Retrospective data • Journal
|
CD4 (CD4 Molecule)
2ms
FLI-1 is expressed in a wide variety of hematolymphoid neoplasms: a special concern in the differential diagnosis. (PubMed, Clin Exp Med)
FLI-1 expression can lead to diagnostic confusion, especially in small blue round cell tumors, such as lymphoblastic lymphoma, plasmablastic lymphoma, and plasma cell myeloma, when distinguishing tumors positive for CD99 and CD56 without CD3, CD20, or CD45. Our findings also suggested the possibility of FLI-1 as a potential prognostic biomarker for plasmablastic lymphoma.
Journal
|
CD20 (Membrane Spanning 4-Domains A1) • PTPRC (Protein Tyrosine Phosphatase Receptor Type C) • NCAM1 (Neural cell adhesion molecule 1) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • CD99 (CD99 Molecule)
2ms
7-Dehydrocholesterol is an endogenous suppressor of ferroptosis. (PubMed, Nature)
We provide validation in neuroblastoma and Burkitt's lymphoma xenografts where we demonstrate that the accumulation of 7-DHC is capable of inducing a shift towards a ferroptosis-resistant state in these tumours ultimately resulting in a more aggressive phenotype. Conclusively, our findings provide compelling evidence of a yet-unrecognized antiferroptotic activity of 7-DHC as a cell-intrinsic mechanism that could be exploited by cancer cells to escape ferroptosis.
Journal
|
DHCR7 (7-Dehydrocholesterol Reductase)
2ms
Oxadiazole Derivatives of Diclofenac as an Anti-proliferative Agent for B-cell Non-Hodgkin Lymphoma: An In vitro and In Silico Studies. (PubMed, Med Chem)
The compound (II) can be a potential therapeutic candidate for B-cell non-Hodgkin lymphoma and deserves further development as a novel anti-lymphoma agent.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • TGFB1 (Transforming Growth Factor Beta 1)
|
BCL2 expression
2ms
PICH deficiency limits the progression of MYC-induced B-cell lymphoma. (PubMed, Blood Cancer J)
Finally, we have corroborated these findings in two human Burkitt lymphoma cell lines and we have found that the death of cancer cells was accompanied by chromosomal instability. Based on these findings, we propose PICH as a potential therapeutic target for Burkitt lymphoma and for other cancers where PICH is overexpressed.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • PLK1 (Polo Like Kinase 1)
|
MYC translocation
2ms
CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies (clinicaltrials.gov)
P1, N=18, Active, not recruiting, Calibr, a division of Scripps Research | N=36 --> 18 | Trial primary completion date: Aug 2023 --> Apr 2024
Enrollment change • Trial primary completion date
|
CLBR001/SWI019
2ms
Ipilimumab and Local Radiation for Selected Solid Tumors (clinicaltrials.gov)
P1, N=3, Terminated, Stanford University | Phase classification: P1/2 --> P1
Phase classification • Combination therapy
|
Yervoy (ipilimumab)
2ms
SOX11 is a novel binding partner and endogenous inhibitor of SAMHD1 ara-CTPase activity in mantle cell lymphoma. (PubMed, Blood)
The sterile alpha motif and histidine-aspartate (HD) domain containing protein 1 (SAMHD1) is a deoxynucleoside triphosphate triphosphohydrolase with ara-CTPase activity that confers cytarabine (ara-C) resistance in several haematological malignancies. In SOX11-negative MCL, SOX11-mediated ara-CTPase inhibition could be mimicked by adding the recently identified SAMHD1 inhibitor hydroxyurea. Taken together, our results identify SOX11 as a novel SAMHD1 interaction partner and its first known endogenous inhibitor with potentially important implications for clinical therapy stratification.
Journal
|
SOX11 (SRY-Box Transcription Factor 11)
|
SOX11 expression
|
cytarabine • hydroxyurea
3ms
Clinical study of mature B-cell lymphoma in 11 children with chromosome 11 long-arm abnormalities (PubMed, Zhonghua Xue Ye Xue Za Zhi)
The incidence of MBCL with 11q abnormalities in children is low, clinical symptoms are mild, and progression is slow. The absence of MYC, BCL2, BCL6 rearrangements, C-MYC negative and 11q abnormalities on FISH is an important diagnostic indicator, and reducing the intensity of chemotherapy can improve prognosis.
Journal • IO biomarker
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
MYC expression • MYC rearrangement • BCL6 rearrangement • BCL2 rearrangement • MYC positive • MYC negative
3ms
waveLINE-001: A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) (clinicaltrials.gov)
P1, N=91, Completed, VelosBio Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | Active, not recruiting --> Completed | N=330 --> 91
Trial completion • Enrollment change
|
zilovertamab vedotin (MK-2140)
3ms
Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas (clinicaltrials.gov)
P=N/A, N=203, Active, not recruiting, Children's Oncology Group | Trial completion date: Dec 2023 --> Dec 2024
Trial completion date
3ms
Enrollment change • Trial withdrawal
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
|
gemcitabine • Rituxan (rituximab) • cyclophosphamide • Zolinza (vorinostat) • clofarabine • busulfan
3ms
Human leukocyte antigen-DQA1*04:01 and rs2040406 variants are associated with elevated risk of childhood Burkitt lymphoma. (PubMed, Commun Biol)
The higher risk rs2040406(G) variant for BL is associated with decreased HLA-DQB1 expression in eQTLs in EBV transformed lymphocytes. Our results support the role of HLA variation in the etiology of BL and suggest that a promising area of research might be understanding the link between HLA variation and EBV control.
Journal
|
HLA-DQB1 (Major Histocompatibility Complex, Class II, DQ Beta 1) • HLA-DQA1 (Major Histocompatibility Complex, Class II, DQ Alpha 1)
3ms
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma (clinicaltrials.gov)
P1/2, N=145, Recruiting, National Cancer Institute (NCI) | Phase classification: P1b/2 --> P1/2
Phase classification
|
BCL2 (B-cell CLL/lymphoma 2) • BCL6 (B-cell CLL/lymphoma 6)
|
BCL6 rearrangement • BCL2 rearrangement
|
Venclexta (venetoclax) • Imbruvica (ibrutinib) • lenalidomide • Gazyva (obinutuzumab) • prednisone
3ms
The potential role of Epstein-Barr Virus in breast cancer development. (PubMed, Cell Mol Biol (Noisy-le-grand))
They have no relationship with EBV infection and, consequently, LMP1 expression. LMP1 expression was not shown to be linked with patient age, tumor grade, tumor size, or lymph node invasion.
Journal
|
HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor)
|
HER-2 overexpression
3ms
Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease (clinicaltrials.gov)
P2, N=135, Active, not recruiting, Fred Hutchinson Cancer Center | Trial completion date: Dec 2025 --> Dec 2024
Trial completion date
|
HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • HLA-B (Major Histocompatibility Complex, Class I, B)
|
cyclophosphamide • fludarabine IV • thiotepa • cyclosporin A microemulsion
3ms
Trial completion date
|
EGFR (Epidermal growth factor receptor) • CD34 (CD34 molecule)
3ms
NCI-2019-01493: Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda (clinicaltrials.gov)
P1, N=18, Terminated, Fred Hutchinson Cancer Center | N=40 --> 18 | Trial completion date: Dec 2023 --> Jul 2023 | Recruiting --> Terminated | Trial primary completion date: Dec 2023 --> Jul 2023; Closed per SRC Low Accrual Policy
Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy
|
CD20 (Membrane Spanning 4-Domains A1) • CD4 (CD4 Molecule)
|
doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • prednisone • daunorubicin • Rituxan Hycela (rituximab/hyaluronidase) • methotrexate IV
3ms
Targeting of the CD161 Inhibitory Receptor Enhances T cell-mediated Immunity Against Hematological Malignancies. (PubMed, Blood)
ScRNA-seq data demonstrated that CD161 mAb treatment enhanced expression of cytotoxicity genes by CD4 T-cells as well as a tissue-residency program by CD4 and CD8 T-cells that is associated with favorable survival outcomes in multiple human cancer types. These fully human monoclonal antibodies thus represent potential immunotherapy agents for hematological malignancies.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule) • KLRB1 (Killer Cell Lectin Like Receptor B1)
3ms
Andrographolide inhibits Burkitt's lymphoma by binding JUN and CASP3 proteins. (PubMed, Cancer Chemother Pharmacol)
Andrographolide inhibits the growth of Burkitt's lymphoma by inhibiting JUN and CASP3 proteins.
Journal
|
CASP3 (Caspase 3)
3ms
Phase classification
|
Gazyva (obinutuzumab) • Zynlonta (loncastuximab tesirine-lpyl) • Polivy (polatuzumab vedotin-piiq) • Lunsumio (mosunetuzumab-axgb) • Columvi (glofitamab-gxbm)
3ms
A distinct isoform of lymphoid enhancer binding factor 1 (LEF1) epigenetically restricts EBV reactivation to maintain viral latency. (PubMed, PLoS Pathog)
As LEF1 repression requires histone deacetylase activity through either recruitment of or direct intrinsic histone deacetylase activity, siRNA depletion of LEF1 resulted in increased histone 3 lysine 9 and lysine 27 acetylation at LEF1 binding sites and across the EBV genome. Taken together, these results indicate a novel role for LEF1 in maintaining EBV latency and restriction viral reactivation via repressive chromatin remodeling of critical lytic cycle factors.
Journal
|
LEF1 (Lymphoid Enhancer Binding Factor 1)
3ms
The Aurora kinase inhibitor AT9283 inhibits Burkitt lymphoma growth by regulating Warburg effect. (PubMed, PeerJ)
The reversal of the Warburg effect in BL cells and the subsequent inhibition of cell proliferation and induction of apoptosis were observed by targeting Aurora A and Aurora B with AT9283. This finding may present new therapeutic options and targets for BL.
Journal
|
MYC (V-myc avian myelocytomatosis viral oncogene homolog) • LDHA (Lactate dehydrogenase A) • HIF1A (Hypoxia inducible factor 1, alpha subunit) • HK2 (Hexokinase 2) • PKM (Pyruvate Kinase M1/2)
|
HIF1A expression
|
AT9283